Immunic, Inc. (Nasdaq: IMUX) presented clinical, biomarker, and preclinical data for its investigational drug vidofludimus calcium (IMU-838) across four poster ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA